Celsius Therapeutics

With the impact of biosimilar competition for Humira (adalimumab) playing out as expected, AbbVie Inc. is expanding its offerings in inflammatory bowel disease (IBD), with the acquisition of Celsiu

Servier ’s vorasedinib has shown promise in the Phase III INDIGO trial in low-grade glioma, prompting the firm to turn attention to regulatory filing and supply plans as its broader strategic focus on

The first half of 2022 saw the NASDAQ Biotechnology Index lose a quarter of its value. Despite a tentative recovery since then, the IPO window is barely ajar and valuations remain well below the highs

Neuron23 Inc. aims to take two small molecule drug candidates for neurological diseases into the clinic during the next two years, with $100m from a series C venture capital round that the company an